| |
Etanercept cohort (N = 2725)
|
Biologic-naïve cohort (N = 1517)
|
p†
|
|---|
|
Gender, female
|
1829 (67.1)
|
1023 (67.4)
|
0.8
|
|
Age at onset (years)
|
7.9 ± 4.7
|
7.7 ± 4.6
|
0.18
|
|
Age at baseline (years)
|
12.1 ± 4.4
|
9.8 ± 4.8
|
< 0.0001*
|
|
Disease duration (years)
|
4.1 ± 3.7
|
2.1 ± 2.8
|
< 0.0001*
|
|
JIA category
|
|
Systemic JIA
|
146 (5.3)
|
58 (3.8)
|
0.025*
|
|
RF-negative polyarthritis
|
904 (33.1)
|
415 (27.3)
|
< 0.0001*
|
|
RF-positive polyarthritis
|
223 (8.1)
|
52 (3.4)
|
< 0.0001*
|
|
Persistent oligoarthritis
|
120 (4.4)
|
390 (25.7)
|
< 0.0001*
|
|
Extended oligoarthritis
|
570 (20.9)
|
204 (13.4)
|
< 0.0001*
|
|
ERA
|
486 (17.8)
|
213 (14.0)
|
0.001*
|
|
PsA
|
191 (7.0)
|
138 (9.0)
|
0.017*
|
|
Unclassified JIA
|
85 (3.1)
|
47 (3.0)
|
1.0
|
|
ANA
|
1290 (47.3)
|
725 (47.8)
|
0.8
|
|
HLA-B27
|
643 (23.6)
|
265 (17.5)
|
< 0.0001*
|
|
Pretreatment at baseline
|
|
NSAIDs
|
2478 (90.9)
|
1329 (87.6)
|
0.0007*
|
|
Systemic steroids
|
1434 (52.6)
|
357 (23.5)
|
< 0.0001*
|
|
MTX
|
2358 (86.5)
|
0 (0)
|
< 0.0001*
|
|
Biologics
|
114 (4.2)
|
0 (0)
|
< 0.0001*
|
|
Other DMARDs
|
1232 (45.2)
|
149 (9.8)
|
< 0.0001*
|
|
SFZ
|
415 (15.2)
|
67 (4.4)
|
< 0.0001*
|
|
HCQ
|
228 (8.4)
|
53 (3.5)
|
< 0.0001*
|
|
AZA
|
237 (8.7)
|
14 (0.9)
|
< 0.0001*
|
|
LEF
|
85 (3.1)
|
6 (0.4)
|
< 0.0001*
|
|
CSA
|
140 (5.1)
|
8 (0.5)
|
< 0.0001*
|
|
Chlorambucil
|
19 (0.7)
|
0 (0)
|
0.0004*
|
|
Cyclophosphamide
|
10 (0.4)
|
0 (0)
|
0.0175*
|
|
Gold salts
|
36 (1.3)
|
0 (0)
|
< 0.0001*
|
|
Immunoglobulins
|
48 (1.8)
|
1 (0.1)
|
< 0.0001*
|
|
MMF
|
14 (0.5)
|
0 (0)
|
0.0034*
|
|
Concomitant treatment at baseline
|
|
NSAIDs
|
2158 (79.2)
|
360 (23.7)
|
0.0001*
|
|
Systemic steroids
|
974 (35.7)
|
1394 (91.9)
|
0.0001*
|
|
MTX
|
1867 (68.5)
|
1517 (100.0)
|
< 0.0001*
|
|
Other DMARDs
|
|
SFZ
|
145 (5.3)
|
36 (2.4)
|
0.0001*
|
|
HCQ
|
37 (1.4)
|
14 (0.9)
|
0.24
|
|
AZA
|
80 (2.9)
|
4 (0.3)
|
0.0001*
|
|
LEF
|
59 (2.2)
|
1 (0.1)
|
0.0001*
|
|
CSA
|
57 (2.1)
|
2 (0.1)
|
0.0001*
|
|
Disease activity parameters at baseline
|
|
Active joints
|
6.7 ± 8.1
|
5.8 ± 7.6
|
0.0004*
|
|
Swollen joints
|
5.3 ± 7.4
|
4.8 ± 6.8
|
0.03*
|
|
Tender joints
|
6.5 ± 8.4
|
5.8 ± 7.8
|
0.007*
|
|
PhysVAS
|
52.2 ± 32.3
|
47.2 ± 25.9
|
0.0001*
|
|
PatVAS
|
43.7 ± 27.4
|
39.0 ± 26.0
|
0.0001*
|
|
Joints with LOM
|
7.4 ± 8.9
|
5.7 ± 7.6
|
0.0001*
|
|
CHAQ-DI
|
0.7 ± 0.6
|
0.6 ± 0.6
|
0.0001*
|
|
ESR (mm/h)
|
23.5 ± 23.4
|
24.2 ± 23.0
|
0.35
|
|
CRP (mg/L)
|
16.8 ± 32.7
|
13.9 ± 27.9
|
0.004*
|
|
JADAS10
|
15.3 ± 7.5
|
13.9 ± 7.1
|
0.0001*
|
- Data are shown as n (%), mean ± SD, or n
- JIA juvenile idiopathic arthritis, RF rheumatoid factor, ERA enthesitis-related arthritis, PsA psoriatic arthritis, ANAs antinuclear antibodies, HLA human leucocyte antigen, NSAID nonsteroidal anti-inflammatory drug, MTX methotrexate, DMARD disease-modifying anti-rheumatic drug, SFZ sulfasalazine, HCQ hydroxychloroquine, AZA azathioprine, LEF leflunomide, CSA cyclosporine, PhysVAS physician global assessment of overall well-being, PatVAS parent/patient global assessment of overall well-being, LOM limitation of motion, CHAQ-DI Childhood Health Assessment Questionnaire disability index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, JADAS10 10-joint Juvenile Arthritis Disease Activity Score
- †By t test or Fisher’s exact test, as appropriate
- *p < 0.05
